Insufficient scRNA-seq data for expression of PLA2G2D at single-cell level.
Insufficient scRNA-seq data for expression of PLA2G2D at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 77% | 38.34 | 446 / 578 | 70% | 11.59 | 813 / 1155 |
intestine | 95% | 127.91 | 921 / 966 | 34% | 4.75 | 179 / 527 |
stomach | 69% | 13.01 | 246 / 359 | 37% | 7.37 | 107 / 286 |
lymph node | 0% | 0 | 0 / 0 | 100% | 491.90 | 29 / 29 |
spleen | 100% | 400.70 | 241 / 241 | 0% | 0 | 0 / 0 |
breast | 49% | 7.95 | 227 / 459 | 45% | 7.10 | 505 / 1118 |
prostate | 55% | 11.40 | 134 / 245 | 29% | 2.10 | 147 / 502 |
bladder | 48% | 6.00 | 10 / 21 | 33% | 5.40 | 166 / 504 |
esophagus | 58% | 7.59 | 832 / 1445 | 22% | 2.75 | 41 / 183 |
skin | 17% | 1.42 | 302 / 1809 | 56% | 21.58 | 262 / 472 |
uterus | 32% | 2.33 | 55 / 170 | 34% | 4.60 | 157 / 459 |
tonsil | 0% | 0 | 0 / 0 | 64% | 18.30 | 29 / 45 |
thymus | 36% | 27.32 | 235 / 653 | 28% | 4.86 | 171 / 605 |
kidney | 27% | 6.60 | 24 / 89 | 36% | 4.08 | 321 / 901 |
ovary | 33% | 4.12 | 60 / 180 | 24% | 1.84 | 104 / 430 |
liver | 34% | 3.57 | 76 / 226 | 22% | 3.24 | 91 / 406 |
peripheral blood | 54% | 6.95 | 503 / 929 | 0% | 0 | 0 / 0 |
adipose | 48% | 7.37 | 579 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 4% | 0.28 | 12 / 328 | 41% | 5.54 | 73 / 178 |
blood vessel | 26% | 6.12 | 347 / 1335 | 0% | 0 | 0 / 0 |
brain | 24% | 1.42 | 626 / 2642 | 1% | 0.82 | 9 / 705 |
heart | 12% | 1.01 | 106 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 10% | 0.64 | 25 / 258 | 2% | 0.06 | 5 / 230 |
eye | 0% | 0 | 0 / 0 | 10% | 1.96 | 8 / 80 |
muscle | 2% | 0.33 | 20 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006644 | Biological process | phospholipid metabolic process |
GO_0046337 | Biological process | phosphatidylethanolamine metabolic process |
GO_0006954 | Biological process | inflammatory response |
GO_0046471 | Biological process | phosphatidylglycerol metabolic process |
GO_0042130 | Biological process | negative regulation of T cell proliferation |
GO_0002361 | Biological process | CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation |
GO_0046470 | Biological process | phosphatidylcholine metabolic process |
GO_0016042 | Biological process | lipid catabolic process |
GO_0002864 | Biological process | regulation of acute inflammatory response to antigenic stimulus |
GO_0050482 | Biological process | arachidonic acid secretion |
GO_0005576 | Cellular component | extracellular region |
GO_0004623 | Molecular function | phospholipase A2 activity |
GO_0043395 | Molecular function | heparan sulfate proteoglycan binding |
GO_0008201 | Molecular function | heparin binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0047498 | Molecular function | calcium-dependent phospholipase A2 activity |
GO_0005543 | Molecular function | phospholipid binding |
Gene name | PLA2G2D |
Protein name | Group IID secretory phospholipase A2 (GIID sPLA2) (sPLA2-IID) (EC 3.1.1.4) (PLA2IID) (Phosphatidylcholine 2-acylhydrolase 2D) (Secretory-type PLA, stroma-associated homolog) |
Synonyms | SPLASH |
Description | FUNCTION: Secretory calcium-dependent phospholipase A2 that primarily targets extracellular lipids, exerting anti-inflammatory and immunosuppressive functions . Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines . In draining lymph nodes, selectively hydrolyzes diacyl and alkenyl forms of phosphatidylethanolamines, releasing omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoate and docosahexaenoate that are precursors of the anti-inflammatory lipid mediators, resolvins (By similarity). During the resolution phase of acute inflammation drives docosahexaenoate-derived resolvin D1 synthesis, which suppresses dendritic cell activation and T-helper 1 immune response (By similarity). May act in an autocrine and paracrine manner (By similarity). Via a mechanism independent of its catalytic activity, promotes differentiation of regulatory T cells (Tregs) and participates in the maintenance of immune tolerance (By similarity). May contribute to lipid remodeling of cellular membranes and generation of lipid mediators involved in pathogen clearance. Displays bactericidal activity against Gram-positive bacteria by directly hydrolyzing phospholipids of the bacterial membrane (By similarity). . |
Accessions | ENST00000375105.8 [Q9UNK4-1] Q9UNK4 ENST00000617227.1 [Q9UNK4-2] |